Recent 8-K filings for EVFM
Highest-materiality recent filing
Evofem shareholders reject merger with Aditxt; merger terminated
- Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.
- Evofem terminates Merger Agreement with Aditxt effective Oct 20, 2025; no termination fee paid.
-
Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M
Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.
-
Evofem signs exclusive 5-year distributorship for SOLOSEC in sub-Saharan Africa with Clovis Davis
Exclusive 5-year distribution agreement with Clovis Davis for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.
-
Evofem Biosciences extends maturity of Adjuvant convertible notes by six months
Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.
-
Evofem and Windtree mutually terminate PHEXXI supply agreement, no fees
License and Supply Agreement for PHEXXI manufacturing terminated March 13, 2026, by mutual consent.
-
Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M
Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.
-
Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M
Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.
-
Evofem shareholders reject merger with Aditxt; merger terminated
Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.
-
Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations
Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.
-
Evofem Biosciences issues $1.42M convertible notes and warrants to Aditxt
Aggregate principal amount $1,423,076.92; warrants to purchase 92,407,592 shares.
-
Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries
Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
-
Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut
Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.
-
Evofem issues $1.15M convertible notes to Aditxt as part of merger financing
Issued $1,153,846 principal in senior subordinated convertible notes and warrants to buy 74,925,075 shares to Aditxt.
-
Windtree to manufacture PHEXXI; Evofem expects COGS reduction of 55-60%.
-
Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY
2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.
-
Received OTC notice on Jan 6, 2025: closing bid price below $0.01 for 30 consecutive days violates Minimum Bid Price Requirement.
-
Evofem extends merger outside date with Aditxt to Jan 31, 2025
Fourth Amendment to Amended and Restated Merger Agreement dated Nov 19, 2024.
-
Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.
-
Evofem secures voting agreements for Aditxt merger; Aditxt completes $2.28M preferred investment
Evofem signed voting agreements with Series E-1 stockholders and convertible noteholders to vote in favor of merger with Aditxt subsidiary Adifem.
-
Evofem gets merger support pacts; secured lenders terminate forbearance, declare default
Institutional investors with rights to ~1.09B common shares (via preferred, convertible notes, warrants) agreed to vote for Aditxt merger.
-
Evofem raises $2.28M via private placement of Series F-1 Preferred Stock to Aditxt
Aditxt purchased 2,280 Series F-1 Preferred Stock shares for $2,280,000 in a private placement.
-
Evofem receives $106.8M debt acceleration notice; closes $460K private placement with Aditxt
Future Pak LLC (agent) claims Event of Default under SPA; repurchase price ~$106.8M if all Purchasers exercise Section 5.7 Option.
-
Evofem receives OTCQB delisting notice for bid price below $0.01
Received OTC Markets notice on Aug 28, 2024 for bid price below $0.01 for 30 consecutive trading days.
-
Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M
Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.
-
Evofem, Aditxt sign amended merger with $1.8M cash and preferred stock
Aditxt to pay up to $1.8M cash for Evofem common stock, less dissenting shares; preferred stock exchange also specified.
-
Evofem acquires Solosec from Lupin for up to $84M in contingent consideration
Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.
-
Evofem Q1 net sales down 38% to $3.6M; loss narrows; Aditxt merger progress
Net sales $3.6M vs $5.8M a year ago, attributed to WAC increase cycle and Change Healthcare cyberattack.
-
Evofem reinstates merger with Aditxt after termination, secures $1M payment and new terms
On May 2, Evofem, Aditxt and merger sub reinstated the merger agreement after termination on April 26.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material